Washington University School of Medicine Siteman Cancer Center

Clinical research site in St Louis, Missouri

Part of Washington University in St. Louis

As of July 2026, 2 paid clinical trials are recruiting at Washington University School of Medicine Siteman Cancer Center in St Louis, Missouri. Active studies at this site cover conditions such as Glioblastoma (GBM), Newly Diagnosed Glioblastoma and GBM. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Washington University School of Medicine Siteman Cancer Center (2)

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

21 locations incl. Springdale

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

for Locally Advanced Solid Tumor

20 locations incl. Orange

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05384626·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Explore more

Paid clinical trials in St Louis, MO · Missouri clinical trials

Washington University School of Medicine Siteman Cancer Center

Recruiting clinical trials at Washington University School of Medicine Siteman Cancer Center (2)

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

More research sites in St Louis

Explore more